Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT00381641Phase 2Completed

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

NCT00390325Phase 2Completed

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

NCT00625846Phase 2Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Showing all 3 trials

Research Network

Activity Timeline